Godmet PG2 Tablet is a combination oral hypoglycemic agent containing Glimepiride 2mg, Metformin 500mg, and Pioglitazone 15mg, indicated for the management of type 2 diabetes mellitus. This formulation leverages the complementary mechanisms of its active ingredients to achieve optimal glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which modulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism. The combined action of these agents addresses multiple pathophysiological defects in type 2 diabetes, including insulin resistance and impaired insulin secretion. Godmet PG2 is prescribed as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on monotherapy or dual therapy. Caution is advised in patients with hepatic or renal impairment, heart failure, or a history of lactic acidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Adverse effects may include hypoglycemia, gastrointestinal disturbances, weight gain, and edema.